Clinical Trials Logo

Tocilizumab clinical trials

View clinical trials related to Tocilizumab.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT06087731 Withdrawn - Clinical trials for Thyroid Associated Ophthalmopathy

Efficacy and Safety of Tocilizumab for TAO

Start date: September 23, 2023
Phase: Phase 2
Study type: Interventional

This study aims to evaluate the efficacy and safety of tocilizumab treating Thyroid Associated Ophthalmopathy.

NCT ID: NCT05133635 Withdrawn - Cytokine Storm Clinical Trials

High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

COVID-19 pandemic has spread all over the world, and hospitalization of the patients with COVÄ°D-19 Pneumonia has become a great burden to the Intensive Care Units. Unfortunately there is still no curative method for the disease yet. Intensive Care Units provide general care for the patients; including oxygen therapy, maintenance of the organ systems (e.g., cardiovascular, renal), nutrition, antibiotic therapy for secondary infections, and etc. One of the major problems in COVID-19 is macrophage activation syndrome, also known as cytokine storm. It stems from exaggerated inflammatory response, which causes increased cytokine release and results in clinical deterioration of the patients. Many drugs have been used to prevent this exaggerated inflammation, like corticosteroids, interleukin (IL) receptor blockers, plasma exchange, etc. In this study our aim is to investigate the effectiveness of high dose corticosteroid (methylprednisolone 250 mg for 3 days) and an IL-6 receptor antagonist (tocilizumab) in the treatment of the cytokine storm of the COVID-19 patients.